| scholarly article | Q13442814 |
| P2093 | author name string | Mitchell M Levy | |
| Mitchell P Fink | |||
| Andrew Gettinger | |||
| Howard L Corwin | |||
| Michael J Corwin | |||
| Ronald G Pearl | |||
| Theodore Colton | |||
| Marc J Shapiro | |||
| EPO Critical Care Trials Group | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| P304 | page(s) | 2827-2835 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. | |
| P478 | volume | 288 |
| Q36951498 | A meta-analysis of randomized controlled trials in critically ill patients to evaluate the dose-response effect of erythropoietin |
| Q36180492 | An Epidemiological Study of Anemia and Renal Dysfunction in Patients Admitted to ICUs across the United States. |
| Q35558506 | Anaemia and red blood cell transfusion in the critically ill patient |
| Q37713514 | Anemia and blood transfusion in the critically ill patient with cardiovascular disease |
| Q35804536 | Anemia and blood transfusion in the critically ill patient: role of erythropoietin |
| Q33369437 | Anemia during and at discharge from intensive care: the impact of restrictive blood transfusion practice |
| Q35206685 | Anemia in acute renal failure: role for erythropoiesis-stimulating proteins? |
| Q36716159 | Anemia in cancer and critical care patients: pharmacoeconomic considerations |
| Q33738712 | Anemia in critical illness: insights into etiology, consequences, and management |
| Q39223954 | Anemia in the ICU: are your patients needin' erythropoetin? |
| Q37281589 | Anemia of critical illness |
| Q37243130 | Anemia of inflammation in critically ill patients |
| Q35544773 | Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study |
| Q37781412 | Bench to bedside: A role for erythropoietin in sepsis. |
| Q24799611 | Bench-to-bedside review: iron metabolism in critically ill patients |
| Q36905393 | Blood conservation in the critically ill. |
| Q24805702 | Blood management in intensive care medicine: CRIT and ABC--what can we learn? |
| Q36951995 | Blood management: a primer for clinicians |
| Q50461359 | Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention. |
| Q44876827 | Bloodless lung transplantation in Jehovah's Witnesses: impact on perioperative parameters and outcome compared with a matched control group |
| Q41651933 | Characterization of erythropoietin and hepcidin in the regulation of persistent injury-associated anemia |
| Q63681899 | Clinical Practice Guidelines for supplemental therapies and issues |
| Q42021443 | Clinical and Surgical Strategies for Avoiding or Reducing Allogeneic Blood Transfusions |
| Q42616360 | Combination therapies for traumatic brain injury: prospective considerations |
| Q47432212 | Comment: use of epoetin alfa in critically ill patients |
| Q44928040 | Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness. |
| Q37233036 | Comparison of the effects of erythropoietin and anakinra on functional recovery and gene expression in a traumatic brain injury model. |
| Q51948620 | Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients. |
| Q33358457 | Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients |
| Q35622659 | Critical issues in nephrology |
| Q61757070 | Diagnose und Therapie der Sepsis |
| Q44754456 | Diagnosis and therapy of sepsis |
| Q50073791 | Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult |
| Q21254582 | Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation |
| Q51104563 | Effect of preprinted order form on epoetin alfa prescribing. |
| Q79079819 | Effects of blood transfusion on clinical and functional outcomes in patients with hip fracture |
| Q41918130 | Effects of early parenteral iron combined erythropoietin in preterm infants: A randomized controlled trial |
| Q48356018 | Effects of red blood cell storage time on transfused patients in the ICU-protocol for a systematic review. |
| Q27010635 | Efficacy and Safety of Erythropoietin to Prevent Acute Kidney Injury in Patients With Critical Illness or Perioperative Care: A Systematic Review and Meta-analysis of Randomized Controlled Trials |
| Q37028212 | Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. |
| Q37098040 | Erythropoietic agents and the elderly |
| Q37102020 | Erythropoietic agents for anemia of critical illness |
| Q36905397 | Erythropoietic therapy: cost efficiency and reimbursement |
| Q37781871 | Erythropoietin 2nd cerebral protection after acute injuries: A double-edged sword? |
| Q41195412 | Erythropoietin Reverses Sepsis-Induced Vasoplegia to Norepinephrine Through Preservation of α1D-Adrenoceptor mRNA Expression and Inhibition of GRK2-Mediated Desensitization in Mouse Aorta |
| Q43137414 | Erythropoietin in sepsis: a new use for a familiar drug? |
| Q24800397 | Erythropoietin in the critically ill - is it more than just blood? |
| Q42154729 | Erythropoietin in the critically ill: do we ask the right questions? |
| Q35574024 | Erythropoietin in the intensive care unit: beyond treatment of anemia |
| Q36728816 | Erythropoietin in the neurology ICU |
| Q40447654 | Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. |
| Q35079125 | Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial |
| Q50459269 | Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat. |
| Q24811530 | Erythropoietin response in critically ill mechanically ventilated patients: a prospective observational study |
| Q41969477 | Erythropoietin use in critically ill patients: forest and trees |
| Q42374784 | Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials |
| Q38964021 | Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials |
| Q33666260 | Factors associated with the development of anemia after subarachnoid hemorrhage. |
| Q48231014 | Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients |
| Q38608377 | Harms of off-label erythropoiesis-stimulating agents for critically ill people |
| Q43066492 | High-risk anaemic Jehovah's Witness patients should be managed in the intensive care unit |
| Q50230107 | Hospital-acquired anemia: Facts, consequences and prevention |
| Q33301591 | Impact of delayed initiation of erythropoietin in critically ill patients |
| Q37293172 | Impact of erythropoietin on intensive care unit patients |
| Q51453198 | Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. |
| Q47750440 | Influence of clinical and economical factors on the expert rating of appropriateness of preoperative use of recombinant erythropoietin in elective orthopedic surgery patients |
| Q37113720 | Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS). |
| Q34081761 | Iron dysregulation combined with aging prevents sepsis-induced apoptosis |
| Q55281444 | Iron metabolism in critically ill patients developing anemia of inflammation: a case control study. |
| Q34326877 | Iron supplementation in the intensive care unit: when, how much, and by what route? |
| Q55435803 | Is There a Role for Hematopoietic Growth Factors During Sepsis? |
| Q35840617 | Is there a place for epoetin alfa in managing anemia during critical illness? |
| Q35542863 | Is there an optimal hemoglobin value in the cardiac intensive care unit? |
| Q48185071 | Lipopolysaccharide interference in erythropoiesis in mice |
| Q47359932 | Low-dose erythropoietin treatment is not associated with clinical benefits in severely anaemic Jehovah's Witnesses: a plea for a change |
| Q50803255 | Managing anemia in the critically ill patient. |
| Q36587705 | Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis. |
| Q42409549 | Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock |
| Q35542879 | New treatment strategies for severe sepsis and septic shock |
| Q30357810 | Newly recognized causes of acute lung injury: transfusion of blood products, severe acute respiratory syndrome, and avian influenza. |
| Q38713052 | Optimizing Outcomes in the Jehovah's Witness Following Trauma: Special Management Concerns for a Unique Population |
| Q37367706 | Optimizing anemia management in hospitalized patients with end-stage renal disease |
| Q37946499 | Organ-protective and immunomodulatory effects of erythropoietin--an update on recent clinical trials |
| Q47312808 | Overview of transfusion practices in perioperative and critical care |
| Q36603224 | Oxygen therapeutics: oxygen delivery without blood |
| Q35804498 | Pathophysiology of intensive care unit-acquired anemia |
| Q93390564 | Persistent inflammation and anemia among critically ill septic patients |
| Q33359927 | Pharmacological alternatives to blood transfusion: what is new about? |
| Q34999094 | Predicting late anemia in critical illness |
| Q37634355 | Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM. |
| Q33843623 | Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine |
| Q57345827 | Protein Therapeutic: Production, Application, and Future Scenario |
| Q34728463 | Protein therapeutics: a summary and pharmacological classification |
| Q80854245 | Questionable conclusions about epoetin alfa |
| Q24794906 | Recently published papers: a number of treatment controversies |
| Q37055340 | Recently published papers: predictors, pressors and poietins |
| Q24813329 | Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. |
| Q35106170 | Recommendations for the transfusion management of patients in the peri-operative period. III. The post-operative period |
| Q37982325 | Red Blood Cell Transfusion and Transfusion Alternatives in Traumatic Brain Injury |
| Q38117135 | Red blood cell clearance in inflammation |
| Q46175627 | Reducing postburn injury anemia in a Jehovah's Witness patient |
| Q35544790 | Risk factors for post-ICU red blood cell transfusion: a prospective study |
| Q24799718 | Role of iron in anaemic critically ill patients: it's time to investigate! |
| Q38127584 | Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis |
| Q24799799 | Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? |
| Q36995847 | Sepsis: a clinical update. |
| Q37562996 | Severe sepsis and septic shock: management and performance improvement. |
| Q36946004 | Short-term benefits and risks of intravenous iron: a systematic review and meta-analysis |
| Q43276193 | Surgical intensive care medicine. Current therapy concepts for septic diseases |
| Q64126988 | Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock |
| Q38433744 | Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. |
| Q29615429 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 |
| Q24644984 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 |
| Q35057544 | Targeted intracellular delivery of proteins with spatial and temporal control |
| Q90003169 | The Effect of Recombinant Human Erythropoietin on Bacterial Growth: A Dual-Edged Sword |
| Q64111058 | The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition |
| Q27339343 | The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition |
| Q64991566 | The Future of Critical Care Lies in Quality Improvement and Education. |
| Q44721292 | The effect of waiving consent on enrollment in a sepsis trial |
| Q50733075 | The prevalence and characteristics of anaemia at discharge home after intensive care. |
| Q35813075 | The top ten list of randomized controlled trials in transfusion medicine |
| Q86828235 | Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: a systematic review |
| Q34145971 | Transfusion practice in the intensive care unit: a 10-year analysis. |
| Q34991206 | Transfusion protocol in trauma |
| Q35115570 | Update of acute kidney injury: intensive care nephrology |
| Q35668759 | Use of epoetin alfa in critically ill patients |
| Q35778123 | Use of exogenous erythropoietin in critically ill patients |
| Q84254474 | [Anemia and transfusion therapy: an update] |
| Q50782129 | [Erythropoietin treatment in critically ill children] |
| Q81452760 | [Prevalence and treatment of anemia in critically ill patients] |
Search more.